GeoVax Labs (GOVX) Notes Payables (2018 - 2024)

GeoVax Labs (GOVX) posted quarterly Notes Payables of $142292.0 for Q2 2024, down 22.18% quarter-over-quarter from $182844.0 in Q1 2021.

GeoVax Labs (GOVX) Notes Payables (2018 - 2024) Analysis & Trends

GeoVax Labs (GOVX) has reported Notes Payables for 5 consecutive years, with $142292.0 the latest figure, recorded in Q2 2024.

In Q2 2024, Notes Payables changed N/A year-over-year to $142292.0; the TTM figure through Jun 2024 stood at $142292.0 (changed N/A YoY), while the FY2020 annual figure was $183326.0, up 1366.61% from the prior year.
Notes Payables slipped to $142292.0 in Q2 2024 per GOVX's latest filing, from $182844.0 in the prior quarter.
Across five years, Notes Payables topped out at $183326.0 in Q4 2020 and bottomed at $12048.0 in Q1 2020.
Historically, Notes Payables has averaged $147578.8 across 3 years, with a median of $182481.5 in 2020.
Annual changes were most pronounced in 2020 — Notes Payables slipped 3.62% — and 2021, when it jumped 1417.63%.
GeoVax Labs' Notes Payables stood at $183326.0 in 2020, then decreased by 0.26% to $182844.0 in 2021, then decreased by 22.18% to $142292.0 in 2024.
Business Quant data shows GOVX's Notes Payables at $142292.0 in Q2 2024, $182844.0 in Q1 2021, and $183326.0 in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.41 Bn	131.56 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.14 Bn	78.15 Bn	3.93 Bn
3	Argenx Se	65.52 Bn	60.34 Bn	1.37 Bn
4	Moderna	58.21 Bn	53.07 Bn	52.00 Mn
5	BeOne Medicines	42.15 Bn	37.05 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.62 Bn	28.31 Bn	992.69 Mn
7	BioNTech SE	27.95 Bn	9.56 Bn	668.28 Mn
8	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
9	Royalty Pharma	27.30 Bn	26.46 Bn	-
10	GeoVax Labs	2.93 Mn	-209,363.39	-

Download Data